Please note this program is intended for US healthcare professionals (HCPs) only. This program is sponsored by AbbVie and is not eligible for CME credits. This is an educational event intended only for appropriate healthcare professionals. Spouses, guests, and other individuals who are not the intended audience of this educational program are not permitted to attend. Healthcare professionals who are subject to federal, state or local laws or government ethics restrictions may not attend this event.
This webinar will examine the psychosocial impact of vitiligo and examine how timely, individualized care can improve quality of life and patient outcomes.
Understand the impact of the psychosocial burden of vitiligo on patients
Explore how strategies for timely and sustained clinical intervention could improve quality of life and optimize patient outcomes
Explore the importance of setting personalized treatment goals and expectations, tailored to individual patient needs and recognizing progress through meaningful goal achievement
Join us LIVE!
Brought to you by
ABBV-US-02401-E
Chronic hand eczema (CHE) can disrupt daily life and confidence. Explore the latest mechanisms behind CHE including immune pathways and barrier dysfunction and discover advanced treatments from topical breakthroughs to targeted systemic therapies. Learn practical strategies to personalize care, manage triggers, and empower patients to break the flare cycle for lasting relief.
Describe the clinical presentation, epidemiology, and impact of chronic hand eczema on patients’ daily lives.
Differentiate the major subtypes of chronic hand eczema and understand their specific disease burdens.
Review the immunologic and barrier-related mechanisms underlying each CHE subtype and how these inform targeted therapies.
Apply evidence-based strategies for assessing disease severity and selecting appropriate treatment options, including topical, systemic, and emerging therapies.
Integrate knowledge of CHE pathophysiology, subtypes, and management into practical approaches to improve patient outcomes and quality of life.
Join us LIVE!
Be part of the experience—gain valuable insights and real-time engagement!
Brought to you by
Please note this program is intended for US healthcare professionals (HCPs) only. This program is sponsored by AbbVie and is not eligible for CME credits. This is an educational event intended only for appropriate healthcare professionals. Spouses, guests, and other individuals who are not the intended audience of this educational program are not permitted to attend. Healthcare professionals who are subject to federal, state or local laws or government ethics restrictions may not attend this event.
This webinar will examine the psychosocial impact of vitiligo and examine how timely, individualized care can improve quality of life and patient outcomes.
Discuss common misconceptions and underlying pathogenesis of vitiligo
Understand the impact of the psychosocial burden of vitiligo on patients
Explore the importance of setting personalized treatment goals and expectations, tailored to individual patient needs, and recognizing progress through meaningful goal achievement
Join us LIVE!
Be part of the experience—gain valuable insights and real-time engagement!
Brought to you by
ABBV-US-02401-E
Visit ADVENTprogram.com to discover more resources on prurigo nodularis and other diseases with underlying type 2 inflammation
Please note this program is intended for US healthcare professionals (HCPs) only. This program is sponsored by Incyte Corporation and is not eligible for CME credits. This is an educational event intended only for appropriate healthcare professionals. Spouses, guests, and other individuals who are not the intended audience of this educational program are not permitted to attend. Healthcare professionals who are subject to federal, state or local laws or government ethics restrictions may not attend this event.
Please join us for an expert-led discussion on the pathophysiology of vitiligo, challenges in disease management, goals of therapy, and best practices for patient communication and shared decision-making. We will also gain perspectives from a patient living with vitiligo, to better understand the impact of disease and how to support shared decision-making.
Join an expert-led discussion on the pathophysiology of vitiligo, challenges in disease management, goals of therapy, and best practices for patient communication and shared decision-making
Gain perspectives from a patient living with vitiligo, to better understand the impact of disease and how to support shared decision-making
Understand the indicated patient population for treatment
Join us live!
Be part of the experience—this webinar will not be recorded, so don’t miss out!
Brought to you by
Incyte and the Incyte logo are registered trademarks of Incyte
© 2025, Incyte. MAT-DRM-01633 03/25
Visit ADVENTprogram.com to discover more resources on prurigo nodularis and other diseases with underlying type 2 inflammation
This program is sponsored by, and the speaker is presenting on behalf of, Lilly USA, LLC. It is being presented consistent with FDA guidelines and is not approved for continuing education credit.
Please see Prescribing Information and Patient Information at the product theater or on https://ebglyss.lilly.com.
Please see Instructions for Use included with the device.EBGLYSS® and its delivery device base are trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.
Join us for "Explore EBGLYSS® (lebrikizumab-lbkz)", an event where a clinician will discuss the efficacy and safety of EBGLYSS. This program features early and long-term data, safety, dosing information, and real-world experience from patient cases.
Join an expert-led discussion on the pathophysiology of vitiligo, challenges in disease management, goals of therapy, and best practices for patient communication and shared decision-making
Gain perspectives from a patient living with vitiligo, to better understand the impact of disease and how to support shared decision-making
Understand the indicated patient population for treatment
Join us live!
Be part of the experience—this webinar will not be recorded, so don’t miss out!
Sponsored by
Brought to you by
Incyte and the Incyte logo are registered trademarks of Incyte
© 2025, Incyte. MAT-DRM-01633 03/25
Visit ADVENTprogram.com to discover more resources on prurigo nodularis and other diseases with underlying type 2 inflammation
This event is brought to you by Eli Lilly and Company. This is not a congress-endorsed event and is not part of official programming for a congress. No CME credits will be given for attendance.
Join us for "Explore EBGLYSS® (lebrikizumab-lbkz)", an event where a clinician will discuss the efficacy and safety of EBGLYSS. This program features early and long-term data, safety, dosing information, and real-world experience from patient cases.
Understand the mechanism of action of lebrikizumab-lbkz in targeting IL-13
Review clinical trial data on the efficacy and safety of EBGLYSS™
Identify appropriate patient candidates for lebrikizumab-lbkz
Discuss strategies for integrating lebrikizumab-lbkz into clinical practice
Join us live! Be part of the experience—don’t miss out!
Sponsored by
Visit ADVENTprogram.com to discover more resources on prurigo nodularis and other diseases with underlying type 2 inflammation
MAT-US-2407348 – v1.0 – P Exp Date: 01/10/2025
Warnings – Do not use EBGLYSS if you are allergic to lebrikizumab-lbkz or to any of the ingredients in EBGLYSS. See the Patient Information leaflet that comes with EBGLYSS for a complete list of ingredients.
Before using
Before using EBGLYSS, tell your healthcare provider about all your medical conditions, including if you:
Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
Possible side effects
EBGLYSS can cause serious side effects, including:
The most common side effects of EBGLYSS include:
These are not all of the possible side effects of EBGLYSS. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
How to take
Learn more
EBGLYSS is a prescription medicine available as a 250 mg/2 mL injection prefilled pen or prefilled syringe. For more information, call 1-800-545-5979 or go to ebglyss.lilly.com
This summary provides basic information about EBGLYSS but does not include all information known about this medicine. Read the information that comes with your prescription each time your prescription is filled. This information does not take the place of talking to your doctor. Be sure to talk to your doctor or other healthcare provider about EBGLYSS and how to take it. Your doctor is the best person to help you decide if EBGLYSS is right for you.
LK CON BS AD APP
EBGLYSS™ (EHB-glihs) is an injectable medicine used to treat adults and children 12 years of age and older who weigh at least 88 pounds (40 kg) with moderate-to-severe eczema (atopic dermatitis) that is not well controlled with prescription therapies used on the skin (topical), or who cannot use topical therapies. EBGLYSS can be used with or without topical corticosteroids.
It is not known if EBGLYSS is safe and effective in children less than 12 years of age or in children 12 years to less than 18 years of age who weigh less than 88 pounds (40 kg).
Live Non-CME
Join us for “Explore EBGLYSS® (lebrikizumab-lbkz)”, an event where a clinician will discuss the efficacy and safety of EBGLYSS. This program features early and long-term data, safety, dosing information, and real-world experience from patient cases.
Live Non-CME Lecture
Live Non-CME
Join us for “Explore EBGLYSS® (lebrikizumab-lbkz)”, an event where a clinician will discuss the efficacy and safety of EBGLYSS. This program features early and long-term data, safety, dosing information, and real-world experience from patient cases.
Live Non-CME Lecture
2/25/25 | 5:00 PM PT
2/25/25 | 5:00 PM PT
2/25/25 | 5:00 PM PT
1/14/25 | 5:00 PM PT
1/14/25 | 5:00 PM PT
11/5/24 | 5:00 PM PT
2/25/25 | 5:00 PM PST
6/4/24 | 5:00 PM PST
3/12/24 | 5:00 PM PST
6/4/24 | 5:00 PM PST
6/4/24 | 5:00 PM PST
LearnSkin is a dedicated group of dermatologists and integrative medicine practitioners with a mission to support professionals in dermatology. Their goal is to share the latest scientific research and treatment options in dermatology for both Western and Eastern medicine to meet the growing demand for responsible, quality, and evidence-based education bridging conventional and complementary medical approaches.
LearnSkin master classes, programs, and events are designed to provide clinicians like you with skills that expand past what was learned in school, residency, and traditional conferences with the hope you inspire change in your patients and reach better outcomes in their overall care.

RAFFLE PRIZES